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Abstract
Background: The risk of severe adverse events following treatment of onchocerciasis with ivermectin in areas co-endemic
with loiasis currently compromises the development of control programmes and the treatment of co-infected individuals.
We therefore assessed whether doxycycline treatment could be used without subsequent ivermectin administration to
effectively deliver sustained effects on Onchocerca volvulus microfilaridermia and adult viability. Furthermore we assessed
the safety of doxycycline treatment prior to ivermectin administration in a subset of onchocerciasis individuals co-infected
with low to moderate intensities of Loa loa microfilaraemia.
Methods: A double-blind, randomized, field trial was conducted of 6 weeks of doxycycline (200 mg/day) alone, doxycycline
in combination with ivermectin (150 mg/kg) at +4 months or placebo matching doxycycline + ivermectin at +4 months in
150 individuals infected with Onchocerca volvulus. A further 22 individuals infected with O. volvulus and low to moderate
intensities of Loa loa infection were administered with a course of 6 weeks doxycycline with ivermectin at +4 months.
Treatment efficacy was determined at 4, 12 and 21 months after the start of doxycycline treatment together with the
frequency and severity of adverse events.
Results: One hundred and four (60.5%) participants completed all treatment allocations and follow up assessments over the
21-month trial period. At 12 months, doxycycline/ivermectin treated individuals had lower levels of microfilaridermia and
higher frequency of amicrofilaridermia compared with ivermectin or doxycycline only groups. At 21 months,
microfilaridermia in doxycycline/ivermectin and doxycycline only groups was significantly reduced compared to the
ivermectin only group. 89% of the doxycycline/ivermectin group and 67% of the doxycycline only group were
amicrofilaridermic, compared with 21% in the ivermectin only group. O. volvulus from doxycycline groups were depleted of
Wolbachia and all embryonic stages in utero. Notably, the viability of female adult worms was significantly reduced in
doxycycline treated groups and the macrofilaricidal and sterilising activity was unaffected by the addition of ivermectin.
Treatment with doxycycline was well tolerated and the incidence of adverse event to doxycycline or ivermectin did not
significantly deviate between treatment groups.
Conclusions: A six-week course of doxycycline delivers macrofilaricidal and sterilizing activities, which is not dependent
upon co-administration of ivermectin. Doxycycline is well tolerated in patients co-infected with moderate intensities of L. loa
microfilariae. Therefore, further trials are warranted to assess the safety and efficacy of doxycycline-based interventions to
treat onchocerciasis in individuals at risk of serious adverse reactions to standard treatments due to the co-occurrence of
high intensities of L. loa parasitaemias. The development of an anti-wolbachial treatment regime compatible with MDA
control programmes could offer an alternative to the control of onchocerciasis in areas of co-endemicity with loiasis and at
risk of severe adverse reactions to ivermectin.
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Introduction
Onchocerciasis (also known as River Blindness) is a chronic
disease induced by the filarial nematode Onchocerca volvulus. An
estimated 37 million individuals are infected worldwide with 90
million at risk of infection, mainly in Sub-Saharan Africa. Adult
worm infections establish within subcutaneous nodules (onchocer-
comas) and produce microfilariae (mf), which parasitize skin and
eye tissues. Mf are the transmissive stage for black fly vectors and
are also responsible for the major disease pathologies of
onchocerciasis, including intense troublesome itching, dermatitis,
atrophy, visual impairment and blindness.
Currently, the only drug available to treat onchocerciasis is
ivermectin (MectizanTM, Merck). Ivermectin is generally a safe
and effective microfilaricide and has been used successfully in
community-directed treatment programs aimed at both reducing
the burden of disease and controlling transmission since 1987
[1,2]. Ivermectin has some macrofilaricidal activity against female
adult worms after 6 years of exposure [3], or when given
repeatedly at three-monthly intervals [4,5]. Higher doses of
ivermectin do not improve on this activity and such regimens
are contraindicated due to the occurrence of visual problems [6].
Another anti-filarial drug, diethylcarbamazine (DEC), is also
contraindicated due to the incidence of treatment-associated
blindness and the frequent development of potentially life
threatening adverse reactions, known as Mazzotti Reactions [7,8].
There are three major limitations of a sole reliance on
ivermectin for onchocerciasis control. Firstly, its use in areas co-
endemic with Loa loa, a tissue dwelling filariae that gives rise to
blood circulating mf and found principally in forested regions in
Africa. Reports of severe adverse reactions (SAE), including
encephalopathy, coma and death, in the Central Africa region
following mass distribution of ivermectin have introduced serious
concerns and disruptions to onchocerciasis control programs [8].
Although the mechanism of ivermectin-associated SAE has not
been fully elucidated, L. loa mf have been detected in the cerebral
spinal fluid of patients suffering severe adverse reactions,
indicating that mf can cross the blood brain barrier. The intensity
of L. loa mf in the blood has been determined to be a major risk
factor in the development of SAE [8].
Secondly, because ivermectin principally targets the mf stage,
continuous delivery of annual treatment is required for at least 15–
17 years to interrupt transmission as demonstrated in some
endemic areas of Africa [9]. In other endemic areas of Africa this
strategy is unlikely to lead to the interruption of transmission due
in part to civil strife and conflict, insufficient health infrastructure
and political commitment to funding for sustained control
programmes, which together compromise the eradicability of
onchocerciasis in Africa [10].
The third limitation is that such a long term, community-based
strategy based on a single drug intervention is potentially vulnerable
to the development of drug resistance. Recent reports from Ghana
show evidence of sub-optimal efficacy of ivermectin in communities
receiving 6–18 rounds of treatment [11,12,13]. Parasites from these
communities show genetic changes associated with resistance to
ivermectin in other nematodes and increase the concern of
resistance to ivermectin developing in onchocerciasis [14,15].
Considering the absence of any safe alternative to ivermectin,
there is an urgent need to identify novel anti-filarial drugs. An
ideal alternative would exhibit curative (macrofilaricidal) or
permanent sterility and have minimal treatment-associated side
effects and be safe to use in patients co-infected with L. loa.
A promising approach is to use antibiotics such as doxycycline
to target not the filariae itself, but the Wolbachia endosymbiotic
bacterium that is found in all life stages of O. volvulus. Pilot, open-
labelled trials in onchocerciasis have demonstrated that 6-week
courses of 100 mg/day oral doxycycline cause .90% reductions
in Wolbachia levels from filarial tissues followed by an almost
complete and sustained absence (12–18 months) of mf from the
skin [16,17,18]. Deleterious effects on embryogenesis were
determined by histological assessment of extirpated nodules.
However, a clear adulticidal effect of doxycycline could not be
determined in onchocerciasis patients after 18 months [18]. More
recent placebo controlled trials with extended follow-up analysis
have detected significant macrofilaricidal activity 21–27 months
after receiving 4 to 6 week courses of 200 mg doxycycline [19] or a
5-week course of 100 mg doxycycline [20].
As L. loa is free of Wolbachia symbionts [21,22] antibiotic therapy
is not an option for their treatment. This, however, could be an
advantage for the treatment of concomitant onchocerciasis or
lymphatic filariasis with antibiotics in individuals co-infected with
L. loa without the risk of microfilaricidal induced SAE.
We therefore carried out a randomized, double-blind, placebo
controlled field trial to assess the efficacy and safety of a six-week
course of 200 mg/day oral doxycycline with or without ivermectin
for the treatment of onchocerciasis alone and in patients co-
infected with L. loa. A proportion of the onchocerciasis patients
were also co-infected with Mansonella perstans. Our primary
objectives were to measure changes in a) O. volvulus mf levels in
the skin, b) Wolbachia levels in adult O. volvulus tissues, c)
embryogenesis within female O. volvulus uteri and d) adult motility
and viability. Secondary objectives were to measure the incidence
and severity of adverse events and changes in L. loa and M. perstans
microfilaraemia.
Methods
Ethics statement and trial registration
The experimental protocol for this study was designed in
accordance with the general ethical principles outlined in the
Author Summary
The control of onchocerciasis in Africa relies on the
sustained delivery of ivermectin. In certain areas, annual
treatments delivered with high population coverage for at
least 15–17 years can break transmission. In other endemic
settings this strategy alone is thought to be insufficient to
eradicate the disease. One of the major limitations occurs
in areas that are co-endemic with another filarial infection
caused by Loa loa, due to the risk of a rare severe adverse
event associated with the rapid killing of L. loamicrofilariae
in heavily parasitized individuals. There are also concerns
over recent evidence of reduced efficacy of ivermectin and
the possible development of resistance. An alternative
approach is to target the Wolbachia bacterial endosymbi-
onts of Onchocerca volvulus with the antibiotic, doxycy-
cline. In an area of Cameroon co-endemic for onchocer-
ciasis and loiasis we conducted a trial comparing
doxycycline with or without ivermectin treatment to
ivermectin treatment alone. A six-week course of doxycy-
cline delivers macrofilaricidal and sterilizing activities,
which is not dependent upon co-administration of
ivermectin. Doxycycline is well tolerated in patients co-
infected with moderate intensities of L. loa microfilariae.
The trial indicates that anti-wolbachial therapy is a feasible
alternative to ivermectin in communities co-endemic for
onchocerciasis and loiasis.
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Declaration of Helsinki. The trial was approved by ethics
committees of the Tropical Medicine Research Station, Kumba
and the Research Ethics Committee of The Liverpool School of
Tropical Medicine. Written informed consent was obtained from
all participants, with the exception of those who were illiterate,
where a literate witness signed on behalf of the participant and the
participant added a thumbprint. The trial is registered with the
current controlled trials registry, no: ISRCTN48118452.
Participants
The trial was community based and was undertaken in 6 satellite
villages (Bifang, Ebendi, Eka, Ngalla, Dinku and Olurunti) of the
market town of Widikum, in the North West Province of Cameroon
(between latitude 5u N 43–5u N 54 and between longitude 9u E 41–
9u E 44) starting on 1st July 2003 and finishing on 31st March 2005.
The area is hyperendemic for onchocerciasis with a community
prevalence of Loa loa ranging from 3.36%–14.29% [23]. Nodu-
lectomy surgery was performed at Batibo Hospital under the
direction of The District Health Officer. Individuals eligible for
participation were adults of both sexes aged 15–60, with a minimum
body weight of ./ = 40 Kg, in good health without any clinical
condition requiring chronic medication. Mf counts were assessed
microscopically following skin biopsy using a Walser skin punch.
Hepatic and renal function and pregnancy were assessed by dipstick
chemistry. Exclusion criteria encompassed an O. volvulus microfilar-
ial load ,10 mf/mg, a L. loa microfilarial load .8000 mf/ml,
hepatic and renal enzymes outside of normal ranges (AST
[0–40 IU/l, ALT [0–45 IU/l] and creatinine [3–126 mmol/l])
pregnancy, lactation, intolerance to ivermectin, alcohol or drug
abuse or anti-filarial therapy in the last 12 months.
Intervention
Participants received 26100 mg capsules of doxycycline (Vibra-
mycinTM, Pfizer) or matching placebo supplied by the manufac-
turer, daily, for a total of 42 days following a breakfast meal. Four
months after the start of treatment, participants received an oral
dose of 150 mg/kg ivermectin (MectizanTM, Merck & Co. Inc.) or
dummy pill (non-matching lactose tablet). Treatment was delivered
by trained community distributors who gave the drug/placebo to
the participants and witnessed them swallowing the tablets.
Outcomes
Outcome measurements encompassed: a) the number of mf
present in skin snip biopsies taken at baseline, 4, 12 and 21 months
after the start of treatment, b) the quantity of a Wolbachia single
copy gene (Wolbachia surface protein; wsp) within extirpated nodule
tissue 21 months after the start of treatment and the immunohis-
tochemical staining of Wolbachia within adult O. volvulus tissues 21
months after the start of treatment, c) the histological assessment of
the frequency of embryonic stages present within female O. volvulus
uteri 21 months after the start of treatment, d) the detection of
adult O. volvulus motility within onchocercomas using ultrasonog-
raphy e) histological assessment of parasite viability, f) the clinical
monitoring and assessment of adverse reactions during primary
drug allocation (doxycycline) or secondary drug allocation
(ivermectin) in patients singly infected with O. volvulus or co-
infected with L. loa and g) the number of L. loa and M. perstans mf
present in 50 ml thick blood smears taken at baseline, 4, 12 and 21
months after the start of treatment.
Assessment of O. volvulus microfilaridermia
Two skin snip samples of approximately 1 mg were taken from
the rear of the leg using a Walser skin punch. Skin snips were
placed in 200 ml saline containing 2 mM EDTA and incubated
overnight at room temperature. The following day the saline
samples were mounted on glass slides, total numbers of released mf
were counted using a compound microscope and the mean
number of mf/snip was derived.
Assessment of L. loa and M. perstans microfilaraemia
Finger prick blood samples (50 ml) were taken at baseline and 4,
12 and 21 month after the start of treatment. Thick blood smears
were made to count numbers of L. loa and M. perstans mf by
microscopy.
Determination of Wolbachia levels, embryogenic status
and viability
Onchocercomas were surgically removed under local anaesthe-
sia from operable sites. Onchocercomas were halved and fixed in
either 80% ethanol for histology or in stabilisation buffer
(RNAlater, Qiagen) for DNA analysis. Genomic DNA was
extracted and the quantity of Wolbachia wsp was determined by
quantitative PCR as previously described [24]. Ethanol fixed tissue
was embedded in paraffin wax blocks and several sections stained
with haematoxylin and eosin. The embryonic status of the adult
females was determined by counting the number of adult female
cross sections which contained ova, morulae, curled microfilariae
and straight microfilariae. Immunohistochemistry for the detection
of Wolbachia used a polyclonal rabbit antisera raised to B.malayi
Wolbachia surface protein (WSP) at a dilution of 1:2000 [24] and
for viability with a rabbit antisera to lysosomal aspartic protease of
O. volvulus (APR) at a dilution of 1:1000 [25]. The viability of
parasites was assessed using criteria as previously described [19].
In brief, the criteria for dead worms included evidence of
calcification without cuticle or nearly complete adsorbed, loss of
body wall integrity, loss of nuclei and absence of APR staining.
Determination of adult motility
Ultrasonography (USG) was used to examine palpable oncho-
cercomas as previously described [26]. Ultrasound examinations
were performed 21 months after treatment start using a portable
ultrasound system (Sonosite 180 PlusH, Sonosite Washington,
USA) and a linear transducer (L38mm) with frequencies of 7.5–
10 MHz. Patients were examined in a supine position in order to
avoid artefacts due to movements. Each onchocercoma was
scanned in longitudinal and transverse sections to detect motile
adult filariae. The transducer was positioned at the largest
diameter or at the largest echo-free area in case of cystic nodules.
Imaging was carried out in panorama mode to provide optimal
information. The detection of all onchocercomata was recorded
with a camcorder (SONYH PAL handycam, SONY Corp, Japan)
on video tapes. Onchocercomata were identified by a capsule of
connective tissue, lateral shadowing, partly echo-free areas as sign
for necrotic proceedings and acoustic shadowing, reflecting
moving and static fragments of the adult worms [26].
Assessment of adverse events
Clinical monitoring of adverse reactions was undertaken by
community health officers throughout the 6-week period of
doxycycline treatment. Patients were asked by questionnaire for
any side effects of the drugs as per protocol. Adverse events were
assigned scores; 0 = no abnormality, 1 = mild, 2 = moderate and
3 = severe. Individuals were asked to report any signs and
symptoms that were not experienced prior to drug administration.
All symptoms were documented in patients’ treatment cards and
medication or hospitalisation was provided where necessary. For
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the assessment of adverse reactions to ivermectin, a scoring system
previously described was utilized [27]. Incidence and severity of
clinical symptoms consistent with ivermectin-associated adverse
reactions (such as increased body temperature and type and extent
of skin rash) were recorded immediately preceding ivermectin
treatment and forty-eight hours following administration.
Sample size
Based on data from a previous study [17], a reduction in the
(geometric) mean mf load/mg skin of 50% at 6 months was
considered to be clinically significant. Assuming a baseline
(geometric) mean mf load of 9.40 and a standard deviation similar
to that in the previous study, 25 patients would be sufficient to
Figure 1. Trial profile. *All L.loa positive patients were additionally assigned to this group (numbers and dropouts provided in italics).
doi:10.1371/journal.pntd.0000660.g001
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detect such a reduction with 80% power. To allow for up to a 15%
drop-out rate over the study period, 30 patients were recruited into
each treatment group.
Randomization and blinding
Randomization for onchocerciasis was block stratified based on
baseline microfilaridermia. All L. loa co-infected patients were
assigned to doxycycline + ivermectin treatment. Treatment
allocation was assigned by randomized ID code (by JDT and
MJT) and the course of treatment sealed in an envelope for
allocation by the field team and district field officers. All study
personnel and participants were blinded to the doxycycline and
placebo treatment assignment for the duration of the study.
Deviation from protocol
Placebo tablets for assessment of ivermectin adverse events were
not supplied in time for treatment allocation and so unmarked
lactose tablets of similar size, shape and colour were used as an
alternative. The ivermectin and dummy pills were assigned to
individuals in sealed unmarked envelopes before being handed
over to district health officers for drug delivery and these together
with individuals responsible for the clinical assessment of adverse
events were not involved in any subsequent analysis. Due to the
lack of significant differences between groups in the severity or
incidence of adverse reaction, cytokine analysis was not per-
formed.
Statistical analysis
The drop-out rates in the treatment groups were compared
using Kaplan-Meier (survival curve) analyses. The age distribu-
tions and sex ratios of the groups were compared using one-way
ANOVA and the Fisher exact test respectively. O. volvulus
microfilaridermia and wsp copy number measurements were
significantly positively skewed (even after log transformation) as
assessed by the Kolmogorov–Smirnov test of Normality, so were
evaluated using non-parametric analyses; changes in mf counts
Table 1. Characteristics of patient groups that completed the trial (enrolment, treatment allocations and all follow ups).
Infection
group Treatment n
Mean age
(range)1
Sex ratio:
male/female2
Patients with
palpable
onchocercomas
Median O. volvulus
microfilaridermia
mf/snip (range)
Median M. perstans
microfilaraemia
mf/ml (range)
Median L. loa
microfilaraemia
mf/ml (range)
O. volvulus Doxycycline+
Ivermectin
20 35.0 (15-50) 13 (65%)/
7 (35%)
5 (25%) 24.25 (11.00-101.00) – –
O. volvulus +
M.
perstans
Doxycycline +
Ivermectin
12 35.6 (20–50) 7 (58%)/
5 (42%)
7 (58%) 27.50 (10.00–200.00) 40.00 (1.00–560.00) –
O. volvulus
+ L. loa +/2
M. perstans
Doxycycline +
Ivermectin
14 32.1 (15–50) 11 (79%)/
3 (21%)
8 (57%) 35.75 (9.50–145.00) 0.00 (0.00–700.00) 150.00
(20.00–5540.00)
O. volvulus Doxycycline 21 34.8 (15–50) 13 (62%)/
8 (38%)
14 (67%) 23.50 (9.5–124.50) – –
O. volvulus Ivermectin 23 37.9 (22–50) 12 (52%)/
11 (48%)
9 (52%) 32.00 (11.5–154.00) – –
O. volvulus +
M. perstans
Ivermectin 14 34.9 (16–50) 6 (43%)/
8 (57%)
7 (50)% 33.25 (11.5–102.50) 90.00 (1.00–160.00) –
1No significant difference in age distribution between treatment groups [one way ANOVA: F(2,101) = 0.3346, p = 0.7164].
2No significant difference in sex ratios between treatment groups:
(a) Doxycycline + ivermectin (O. volvulus single infection) and doxycycline + ivermectin (L. loa co-infected) separate:Fisher exact test ns.
(b) Doxycycline + ivermectin (O. volvulus single infection) and doxycycline + ivermectin (L. loa co-infected) combined: Fisher exact test ns.
doi:10.1371/journal.pntd.0000660.t001
Table 2. incidence and severity of adverse events during doxycycline and following ivermectin treatment.
Patient Group n
Incidence of adverse
event during 6 week
doxycycline treatment1 n Incidence of adverse reaction 48 h following ivermectin treatment2
None Mild Moderate2 Severe
Doxycycline + Ivermectin
(O. volvulus single infection)
52 6 (11.5%) 42 39 (92.9%) 3 (7.1%) 0 0
Doxycycline + Ivermectin
(O. volvulus + L. loa co-infection)
21 2 (9.5%) 20 17 (85.0%) 3 (15.0%) 0 0
Doxycycline 29 2 (6.9%) 25 22 (88.0%) 3 (12.0%) 0 0
Ivermectin 59 7 (11.9%) 45 38 (84.4%) 5 (11.1%) 2 (4.4%) 0
1No significant differences between the four treatment groups with respect to the frequency of adverse event during 6 week doxycycline treatment. (Fisher exact test:
p = 0.964 n.s.).
2No significant difference in frequencies of adverse reactions between treatment groups: Doxycycline + ivermectin (O. volvulus single infection) and doxycycline +
ivermectin (L. loa co-infected) combined: Fisher exact test p = 0.538 ns.
doi:10.1371/journal.pntd.0000660.t002
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with time from baseline were assessed using Wilcoxon signed rank
tests and differences in mf counts between the treatment groups
were analysed using Mann-Whitney U tests. As group sizes were
small, frequency of amicrofilaridermia, mf in onchocercomatous
tissue, embryonic stages within uteri and adult worm movement
were compared across the treatment groups using Fisher exact
tests. All analyses were performed using the SPSS v11, Stata8 and
GraphPad Prism software packages.
Figure 2. Changes in Onchocerca volvulus microfilaridermia from baseline at 4 months, 12 months and 21 months post treatment
with doxycycline + ivermectin, doxycycline only or ivermectin only. Arrows indicate commencement of intervention (black arrow;
doxycycline, red arrow; ivermectin).
doi:10.1371/journal.pntd.0000660.g002
Table 3. Changes in O. volvulus microfilaridermia at 4, 12 and 21 months after the start of treatment.
Treatment n
Baseline median
microfilaridermia
mf/snip (range)
4 month median
microfilaridermia mf/snip
(range) No. of participants
with amicrofilaridermia (%)
12 month median
microfilaridermia mf/snip
(range) No. of participants
with amicrofilaridermia (%)
21 month median
microfilaridermia mf/
snip (range) No. of
participants with
amicrofilaridermia (%)
Doxycycline + Ivermectin 46 31 (10–200) 16 (0–179) 6 (13.0%) 0 (0–54.5) 35 (76.1%) 0 (0–2) 41 (89.1%)
Doxycycline 21 23.5 (11–124.5) 2 (0–186) 5 (23.8%) 2 (0–57.5) 8 (38.1%) 0 (0–8.5) 14 (66.7%)
Placebo/Ivermectin 37 32 (12–154) 8 (0–121) 7 (18.9%) 1.5 (0–69) 8 (21.6%) 4 (0–141) 8 (21.6%)
Analysis of longitudinal changes in microfilaridermia from baseline per treatment group (Wilcoxon Signed Rank tests):
Doxycycline + ivermectin: p = 0.0295 (* 4 month); p,0.0001 (***12 month); p,0.0001 (*** 21 month)\
Doxycycline: p = 0.2760 (ns, 4 month); p = 0.0020 (** 12 month); p,0.0001 (*** 21 month).
Ivermectin: p = 0.0090 (***4 month); p,0.0001 (***12 month); p = 0.0005 (*** 21 month).
Analysis of differences in microfilaridermia between treatment groups at baseline, 4, 12 and 21 months post treatment (Mann Whitney U tests):
Doxycycline + ivermectin vs ivermectin: p = 0.7381 (ns, baseline); p = 0.2335 (ns, 4 month); p,0.0001 (*** 12 month); p,0.0001 (*** 21 month).
Doxycycline vs ivermectin: p = 0.5712 (ns, baseline); p = 0.2335 (ns, 4 month); p = 0.7214 (ns, 12 month); p = 0.0002 (*** 21 month).
Doxycycline + ivermectin vs doxycycline: p = 0.5841 (ns, baseline); p = 0.1990 (ns, 4 month); p = 0.0025 (*** 12 month); p = 0.1193 (ns, 21 month).
Analysis of amicrofilaridermia frequencies between treatment groups at 4, 12 and 21 months post treatment (Fisher exact tests):
Doxycycline + ivermectin vs ivermectin: p = 0.5417 (ns, 4 month); p,0.0001 (*** 12 month); p,0.0001 (*** 21month).
Doxycycline vs ivermectin: p = 0.7409 (ns, 4 month); p = 0.2265 (ns, 12 month); p = 0.0016 (*** 21month).
Doxycycline + ivermectin vs doxycycline: p = 0.3006 (ns, 4 month); p = 0.0052 (** 12 month); p = 0.0394 (* 21month).
doi:10.1371/journal.pntd.0000660.t003
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Results
Participant flow and recruitment
Figure 1 illustrates the trial profile. One hundred and fifty
onchocerciasis patients fulfilling all entry criteria, were enrolled
into the trial and randomized into one of the three treatment arms.
Twenty-two additional onchocerciasis patients fulfilling all entry
criteria were identified as positive for L. loa infection (below the
safety threshold of 8000 mf/ml) and assigned into doxycycline +
ivermectin regimen.
Adherence to treatment and drop out
102/112 (91%) of the individuals who started treatment
completed the full course of doxycycline and 59/60 (98%)
placebo. For ivermectin 107/123 (87%) and dummy pill 25/27
(93%) individuals completed treatment. Additional drop-outs at
the 4, 12 and 21 month follow-up assessments were 11, 21 and 7,
respectively. Thus, in total, 104 out of 172 enrolled patients (62%)
completed all treatment allocations and all subsequent follow-ups
and were included for outcome analysis. There were no significant
differences in the drop-out patterns over the follow up period
between the three treatment groups (log-rank test of survival
p = 0.718).
The baseline characteristics of these patients are reported in
Table 1. Age and gender did not significantly differ between the
three treatment groups.
Outcome analyses
For the assessment of adverse events, patients co-infected with
L. loa (treated with doxycycline and ivermectin) have been
analysed as a distinct group in order to evaluate whether co-
infection is associated with the occurrence of such events. For all
other outcome analyses, these patients have been combined with
O. volvulus single infected patients receiving doxycycline and
ivermectin.
Occurrence of adverse events during treatment
allocations
Table 2 summarizes the recorded adverse events during the 6-
week primary drug allocation of doxycycline or matching placebo
and 48 hours following the secondary drug allocation of
ivermectin or dummy pill allocation. Adverse events were
recorded in 17 patients during the 6-week period of doxycycline
or matching placebo allocation. The incidence of adverse event
did not significantly deviate between doxycycline- or placebo-
assigned patients or between O. volvulus single infected and O.
volvulus + L. loa co-infected patients assigned doxycycline.
Symptoms were mild and included itching, fever, headache, body
pains and vertigo. One patient administered doxycycline devel-
oped fever and headache, which led to a temporary interruption of
the treatment for 5 days. Anti-malarial drugs were given for three
days and doxycycline treatment resumed after recovery. There
was no evidence or complaint of symptoms consistent with
doxycycline-associated photosensitivity. It was not necessary to
discontinue primary drug allocation in any instance.
Forty-eight hours following ivermectin or dummy pill allocation,
symptoms consistent with adverse reactions were observed in 16
patients (12.1% of all patients present). The majority of the
adverse reactions were graded as mild (14 patients) with two
patients in the ivermectin only group experiencing moderate
adverse reactions. The frequency of either mild or moderate
adverse reaction did not significantly differ between patients
treated with ivermectin following doxycycline intervention and
patients treated with ivermectin following placebo, matching
doxycycline. Furthermore, the frequency of adverse reaction did
not differ between patients treated with ivermectin and patients
treated with a dummy pill.
Reductions in O. volvulus mf
Figure 2 illustrates the changes in O. volvulus mf levels in skin
from baseline. The analysis of these changes is summarized in
Table 3. Baseline, O. volvulus microfilaridermia did not signifi-
cantly differ between treatment groups in the participants who
completed the trial. At 4 months post-doxycycline allocation and
immediately preceding ivermectin allocation, reductions in
microfilaridermia had occurred in all treatment groups compared
with baseline; these were statistically significant both for the
doxycycline and placebo groups assigned for ivermectin alloca-
tion but not for the group assigned to doxycycline alone. No
significant inter-treatment group differences in microfilaridermia
were observable at 4 months. At 12 months post-doxycycline
intervention (8 months post-ivermectin intervention), microfilar-
idermia was significantly reduced in all treatment groups.
However, inter-treatment group differences were also apparent
at this follow up. Doxycycline + ivermectin treated individuals
had lower levels of microfilaridermia compared with both the
ivermectin only and doxycycline only groups. Also, the incidence
of amicrofilaridermia (an absence of detectable mf in the skin)
Table 4. Changes in Wolbachia surface protein expression and wsp DNA copy number in onchocercomas 21 months following
start of treatment.
Treatment
Nodulectomy patients
(total number of onchocercomas)
WSP % +ve1 (no. +ve sections/no.
total sections)
Median wsp copy
number2 (range)
Doxycycline + Ivermectin 12 (14) 0** (0/14) 0* (0–15389)
Doxycycline 7 (12) 0** (0/11) 0* (0–800)
Ivermectin 11 (29) 66.7 (14/21) 484 (0–99805)
1Analysis of the frequency of O. volvulus tissue positively stained with anti-WSP antibody between treatment groups at 21 months post treatment (Fisher exact tests):
Doxycycline + ivermectin vs ivermectin: p = 0 005 (**).
Doxycycline vs ivermectin: p = 0.003 (**).
Doxycycline + ivermectin vs doxycycline: p = 1.000 (ns).
2Analysis of differences in wsp DNA copy number within onchocercomas between treatment groups at 21 months post treatment (Mann-Whitney U-tests):
Doxycycline + ivermectin vs ivermectin: p = 0.015 (*).
Doxycycline vs ivermectin: p = 0.013 (*).
Doxycycline + ivermectin vs doxycycline: p = 0.752 (ns).
doi:10.1371/journal.pntd.0000660.t004
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was significantly higher in doxycycline + ivermectin groups
(76.1%) compared with both the ivermectin only (21.6%) and
doxycycline only (38.1%) groups. At 21 months post-doxycycline
intervention (17 months post-ivermectin intervention), significant
microfilaridermia reductions from baseline persisted in all
treatment groups. Inter-treatment differences between doxycy-
cline + ivermectin and ivermectin groups were also preserved.
Furthermore, the majority (89.1%) of the doxycycline +
ivermectin treatment group were amicrofilaridermic at 21
months, compared with 21.6% in the ivermectin only treatment
group. At 21 months the doxycycline only group also showed
greater reductions in microfilaridermia and increased frequency
of amicrofilaridermia (66.7%) compared with ivermectin only.
When comparing between doxycycline + ivermectin and
doxycycline only at 21 months, the combined treatment group
showed significantly increased frequency of amicrofilaridermia.
Figure 3. Immunohistochemical assessment of Wolbachia and nematode viability within adult O. volvulus tissue derived from trial
patients at 21 months after the start of treatment. A: WSP-specific immunostaining (arrow) of Wolbachia in O. volvulus adult female after
ivermectin only treatment, B: Lack of WSP staining in O. volvulus from a doxycycline + ivermectin treated individual. C: APR staining (arrow) of viable
adult female O. volvulus after ivermectin only treatment. D: Lack of APR staining in a non-viable adult worm from a doxycycline treated individual.
doi:10.1371/journal.pntd.0000660.g003
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Depletion of Wolbachia from adult O. volvulus
Table 4 summarizes the measurements of Wolbachia within
adult O. volvulus derived from extirpated nodules at 21 months.
In total 30 individuals who completed the trial were selected
for nodulectomy (selection based on the presence of palpable
nodules in suitable sites for operation). Wolbachia wsp copy
number, determined from genomic DNA extracted from one
half of each extirpated nodule, was significantly lower in both
doxycycline + ivermectin and doxycycline only treatment
groups, compared with ivermectin only treatment. The
depletion of Wolbachia in doxycycline treatment groups
determined by PCR was corroborated by immunohistochem-
ical staining of Wolbachia WSP within sections of adult O.
volvulus tissues (Table 4, Figure 3). In both doxycycline only
and doxycycline + ivermectin treated individuals, WSP positive
staining was not detected in any of the nodules examined.
These frequencies were significantly lower when compared
with the frequency of positive staining of O. volvulus tissues
derived from patients treated with ivermectin only (67%).
Reductions in O. volvulus embryogenesis
Histological observations of different embryonic stages within
uteri and released mf in nodule tissue are summarized in Table 5.
The frequency of ova, morulae, curled stage and straight stage
embryos within uteri were reduced in female worms derived from
doxycycline + ivermectin treated individuals compared with
ivermectin only treated individuals after 21 months. Similar
reductions in frequency of embryonic developmental stages were
observed in doxycycline only treated individuals compared with
ivermectin only treated individuals. Presence of mf within nodule
Table 5. Histological analysis of embryonic stages within uteri and released mf in onchocercoma tissue.
Treatment
Nodulectomy patients
(total number of
onchocercomas) Uterine contents % +ve (no. +ve cross sections/no. total cross sections)
Released mf5 % +ve
(no. +ve sections/no.
total sections)
Ova1 Morulae2 Curled mf3 Straight mf4
Doxycycline +
Ivermectin
12 (14) 4.0*** (22/546) 2.9*** (16/546) 3.3*** (18/546) 0.9*** (5/546) 19.4* (6/31)
Doxycycline 7 (12) 4.1*** (20/492) 2.0*** (10/492) 2.0*** (10/492) 1.0*** (5/492) 7.4*** (2/27)
Ivermectin 11 (29) 9.0 (123/1363) 9.0 (123/1363) 17.0 (232/1363) 8.0 (109/1363) 47.1 (24/51)
All of the following analyses were performed using Fisher exact tests:
1Analysis of the frequency of ova present within uterine cross sections of female O. volvulus between treatment groups at 21 months post treatment:
Doxycycline + ivermectin vs ivermectin: p,0.001 (***).
Doxycycline vs ivermectin: p,0.001 (***).
Doxycycline + ivermectin vs doxycycline: p = 1.000 (ns).
2Analysis of the frequency of morulae present within uterine cross sections of female O. volvulus between treatment groups at 21 months post treatment:
Doxycycline + ivermectin vs ivermectin: p,0.001 (***).
Doxycycline vs ivermectin: p,0.001 (***).
Doxycycline + ivermectin vs doxycycline: p = 0.428 (ns).
3Analysis of the frequency of curled mf present within uterine cross sections of female O. volvulus between treatment groups at 21 months post treatment:
Doxycycline + ivermectin vs ivermectin: p,0.001 (***).
Doxycycline vs ivermectin: p,0.001 (***).
Doxycycline + ivermectin vs doxycycline: p = 0.251 (ns).
4Analysis of the frequency of straight mf present within uterine cross sections of female O. volvulus between treatment groups at 21 months post treatment:
Doxycycline + ivermectin vs ivermectin: p,0.001 (***).
Doxycycline vs ivermectin: p,0.001 (***).
Doxycycline + ivermectin vs doxycycline: p = 1.000 (ns).
5Analysis of the frequency of released mf present within onchocercoma tissue between treatment groups at 21 months post treatment:
Doxycycline + ivermectin vs ivermectin: p = 0.017 (*).
Doxycycline vs ivermectin: p,0.001 (***).
Doxycycline + ivermectin vs doxycycline: p = 0.263 (ns).
doi:10.1371/journal.pntd.0000660.t005
Table 6. Analysis of USG detection of adult O. volvulus worm movement 21 months after the start of treatment.
Treatment USG patients % +ve detectable adult movement1 (no. +ve/total no.)
Doxycycline + Ivermectin 14 1/14 (7.1%)*
Doxycycline 9 1/9 (11.1%)
Ivermectin 27 12/27 (44.0%)
1Analysis of the frequency of detectable adult O. volvulusmovement within onchocercomas between treatment groups at 21 months post treatment (Fisher exact tests):
Doxycycline + ivermectin vs ivermectin: p = 0.031 (*).
Doxycycline vs ivermectin: p = 0.114 (ns).
Doxycycline + ivermectin vs doxycycline: p = 1.000 (ns).
doi:10.1371/journal.pntd.0000660.t006
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tissue sections were also reduced in both doxycycline + ivermectin
and doxycycline only treated individuals compared with ivermec-
tin only treated individuals at 21 months.
Reductions in adult O. volvulus worm motility
Table 6 documents the results of USG examination. At the 21-
month follow up, 50 patients with palpable nodules undertook
ultrasound examination. Distinct adult worm movement could be
observed within nodules in 44.0% of ivermectin treated patients. In
comparison, the frequencies of detectable worm movement in
doxycycline + ivermectin (7.1%) or doxycycline only (11.1%)
treated individuals was significantly lower only for the doxycycline +
ivermectin group.
Reduction in O.volvulus adult worm viability
At 21 months the proportion of dead adult female worms from
patients in the doxycycline + ivermectin (47%) and doxycycline
only groups (65%) was significantly increased compared to the
ivermectin only group (17%). There was also a significant
reduction in the number of living adult female and male worms
per patient (Table 7).
Changes in L. loa and M. perstans circulating mf
Fluctuations in L. loa microfilaraemia from baseline are
illustrated in Figure 4 and statistical differences summarized in
Table 8. The study design precluded a treatment comparison (all
L. loa patients were assigned doxycycline + ivermectin) and
therefore only longitudinal analyses were undertaken. No
significant changes in L. loa microfilaraemia occurred at 4 months
after doxycycline treatment (immediately preceding ivermectin
intervention). L. loa mf loads were significantly reduced at 12
months and 21 months after the start of doxycycline treatment (8
and 17 months after ivermectin treatment).
M. perstans microfilaraemia had significantly increased from
baseline at 4 months after doxycycline allocation, immediately
preceding ivermectin intervention, in both doxycycline and
placebo treatment groups (Table 9, Figure 5). No inter-group
differences in M. perstans mf levels at 4 months were observable.
At 12 months after the start of doxycycline intervention (8
months following ivermectin intervention) significant reductions
in circulating mf compared with baseline levels had occurred in
doxycycline + ivermectin treated individuals but not ivermectin
only treated individuals. There was also a strong inter-group
difference at 12 months in both M. perstans microfilaraemia and
frequency of amicrofilaraemia (94.7% in doxycycline + iver-
mectin compared with 7.1% in ivermectin only treated
individuals). By the 21-month follow up (17 months following
ivermectin treatment), both treatment groups showed reductions
in M. perstans microfilaraemia compared with baseline. There
were no inter-group differences apparent at this stage with
amicrofilaraemia occurring in the majority of both doxycycline +
ivermectin (84.2%) and ivermectin only (78.6%) treated individuals.
Discussion
The major outcome of this trial is that a 6-week course of
doxycycline alone is a highly effective treatment against onchocerci-
asis, leading to long term and profound suppression of microfilar-
idermia, embryogenesis and significant macrofilaricidal activity
independently of ivermectin administration. It also shows that an
additional treatment with ivermectin does not lead to any
improvement in the macrofilaricidal or sterilising activity of
doxycycline. Furthermore, our trial indicates that doxycycline
treatment is well-tolerated in O. volvulus patients co-infected with low
to moderate levels of L. loa parasitaemias. These findings promote the
use of a doxycycline only regimen to treat onchocerciasis patients co-
infected with L. loa. However, further trials are warranted to test safety
and efficacy of doxycycline treatment in co-infected individuals at risk
of developing serious adverse reactions to ivermectin. Should the
results of such trials support our safety and efficacy findings reported
here, a potential solution will be available to MDA programs
currently disrupted by the threat of L. loa SAE. Previous trials on
lymphatic filariasis that also demonstrated macrofilaricidal activity
with doxycycline alone [28] suggest that this approach could be
extended to co-infections of Wuchereria bancrofti and loiasis.
The results of this trial confirms previous findings in
onchocerciasis and lymphatic filariasis that a course of doxycy-
cline sufficient to deplete Wolbachia by .90% results in the death
Table 7. O. volvulus viability 21 months after the start of treatment.
Treatment Patients Nodules Female worms1 Male worms8 Living worms per patient
all dead all dead Female4 Male9
n n n n (%) n n (%) mean (se) mean (se)
Doxycycline + ivermectin 6 9 15 7 (46.7)2 3 0 1.33 (0.42)5 0.50 (0.34)10
Doxycycline 7 9 20 13 (65.0)3 3 0 1.00 (0.44)6,7 0.43 (0.20)11,12
Ivermectin 13 27 54 9 (16.7) 22 1 (4.5) 3.46 (0.56) 1.62 (0.43)
Female worms.
1Significant differences in proportions of dead worms between the three groups (Fishers exact test: p,0.001).
2Significant difference in proportion of dead female worms compared to ivermectin only group (Fishers exact test: p = 0.033).
3Significant difference in the proportion of dead female worms compared to ivermectin only group (Fishers exact test: p,0.001).
4Assuming a Poisson distribution: significant differences in mean numbers of living worms per patient between the three groups (x2(2) = 16.01, p,0.001.
5placebo + ivermectin vs. doxycycline + ivermectin p = 0.006.
6placebo + ivermectin vs. doxycycline p,0.001.
7doxycycline + ivermectin vs. doxycycline p = 0.578 (ns).
Male worms.
8No significant differences in proportions of dead worms between the three groups (Fishers exact test: p = 1.000).
9Assuming a Poisson distribution: significant differences in mean numbers of living worms per patient between the three groups (x2(2) = 8.86, p = 0.012.
10placebo + ivermectin vs. doxycycline + ivermectin p = 0.029.
11placebo + ivermectin vs. doxycycline p = 0.012.
12doxycycline + ivermectin vs. doxycycline p = 0.850 (ns).
doi:10.1371/journal.pntd.0000660.t007
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of adult worms (reviewed in [29]). Prior to the removal of the
nodules for histochemical and PCR analysis we used ultrasonog-
raphy (USG) to detect the in vivo motility of parasites. The USG
data showed reduced parasite motility in doxycycline +
ivermectin treated individuals compared with the ivermectin
only group and suggests that USG maybe used as a non-invasive
tool to assess potential macrofilaricidal activity prior to histolog-
ical analysis of parasite viability. Histological and PCR analysis
confirmed that doxycycline treatment resulted in loss of Wolbachia
from the adult parasites, with an extensive loss of uterine contents
reflecting a blockage of embryogenesis as previously observed
[18,19].
Treatment with doxycycline + ivermectin or doxycycline
alone is superior to ivermectin in achieving sustained
reductions in skin mf. The kinetics of mf decline are in line
with the different modes of actions of the two drugs. The slow
decline in mf skin levels following doxycycline treatment is
most likely a consequence of the block in embryogenesis
preventing the release of mf into the skin. These kinetics are
beneficial in avoiding the rapid death of mf, which in
individuals with high parasite burden leads to inflammatory
Mazzotti adverse events following anti-filarial drug treatment
and are associated with the release of Wolbachia into the blood
and tissues [30,31]. The low incidence of adverse events
following ivermectin treatment in this trial probably reflect the
relatively low O. volvulus microfilarial burden, which was
further reduced by a reduction in O. volvulus microfilaridermia
levels across all groups from baseline to the 4 month follow-up
time point (prior to ivermectin administration). The absence of
SAE in L. loa co-infected individuals was as expected due to
exclusion of patients with .8000 mf/ml parasitaemias. The
tolerability of treatment with doxycycline is consistent with our
Figure 4. Changes in Loa loa microfilaridermia from baseline at 4 months, 12 months and 21 months post treatment with
doxycycline + ivermectin, doxycycline only or ivermectin only. Arrows indicate commencement of intervention (black arrow; doxycycline,
red arrow; ivermectin).
doi:10.1371/journal.pntd.0000660.g004
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previous experience in more than 1000 treated field trial
volunteers. No experience of severe adverse event or evidence
of photosensitivity has been recorded. For ethical and safety
issues, our study design precluded enrolment of individuals co-
infected with L. loa above the safety threshold for standard
ivermectin treatment (.8000 mf/ml). However, we noted no
additional safety issues in L. loa co-infected patients during
doxycycline allocation. The dropout rate for the trial did not
differ between L. loa positive and negative treatment groups.
Given that our trial demonstrates comparable efficacies of
doxycycline with or without ivermectin, we believe further
trials are warranted to determine the safety of doxycycline
treatments in L. loa patients with .8000 mf/ml with O. volvulus
co-infection. In this regard a trial of community directed
delivery of doxycycline in an area of onchocerciasis and loiasis
co-endemicity has been completed and demonstrates the
feasibility of the use of large-scale doxycycline therapy for
the control of onchocerciasis in such communities [38]. Some
of the communities covered by this trial included those with a
prevalence of loiasis in excess of 40%, where it can be
estimated that more than 5% of this population would have
microfilaraemia levels above the threshold of 8000 mf/ml. The
lack of any SAE to doxycycline therapy in the 12,612 people
that completed the course of treatment provides indirect
evidence that doxycycline therapy appears safe in individuals
with higher L. loa microfilaraemia.
Although the results of this trial show no additional benefit of
ivermectin to the macrofilaricidal and sterilising activity of
doxycycline, the combination of both drugs improves reductions
in O. volvulus mf intensity and frequency of amicrofilaridermia. The
timing of the ivermectin treatment may be sub-optimal and may
be different in populations exposed to ivermectin control rather
than the ivermectin-naı¨ve population treated here.
The changes in L. loa microfilaraemia observed showed no
change from baseline at the 4-month follow-up point. After
ivermectin treatment mf loads were significantly reduced at
both 12 and 21 month after the start of treatment as
anticipated. The changes observed in M. perstans microfilarae-
mia showed a different pattern. At the 4-month follow-up mf
levels had increased in both doxycycline and placebo groups
and no differences between groups was observed. 8 months
after ivermectin treatment there was a striking reduction in mf
loads in the doxycycline group with no change from baseline
levels observed in the ivermectin only group. At the 21-month
follow up both groups showed marked reductions from
baseline and high frequency of amicrofilaraemia. The differ-
ence between doxycycline and ivermectin only groups at the
12-month follow up would be consistent with a recent report
Table 8. Changes in L. loa parasitaemia at 4, 12 and 21 months after the start of treatment.
Treatment n
Baseline median
parasitaemia mf/ml
(range)
4 month median parasitaemia
mf/ml (range) No. of participants
with amicrofilaraemia (%)
12 month median
parasitaemia mf/ml (range)
No. of participants with
amicrofilaraemia (%)
21 month median
parasitaemia mf/ml (range)
No. of participants with
amicrofilaraemia (%)
Doxycycline +
Ivermectin
14 150 130 0* 0**
(20–5540) (0–5820) (0–2440) (0–3840)
6 (37.5%) 11 (68.8%) 10 (62.5%)
Analysis of longitudinal changes in L. loa microfilaraemia from baseline in patients treated with Doxycycline + ivermectin (Wilcoxon Signed Rank tests): 4 month:
(p = 0.623, ns); 12 month: p = 0.049 (*); 21 month: p = 0.010 (**).
doi:10.1371/journal.pntd.0000660.t008
Table 9. Changes in M. perstans parasitaemia at 4, 12 and 21 months after the start of treatment.
Treatment n
Baseline median
parasitaemia mf/ml
(range)
4 month median
parasitaemia mf/ml (range)
12 month median
parasitaemia mf/ml (range)
21 month parasitaemia mf/ml
(range)
No. of participants with
amicrofilaraemia (%)
No. of participants with
amicrofilaraemia (%)
No. of participants with
amicrofilaraemia (%)
Doxycycline + Ivermectin 19 80 280 0*** 0
(1–700) (0–1460) (0–3200) (0–40)
0 18 (94.7%) 16 (84.2%)
Ivermectin 14 90 140 190 0
(1–160) (0–1940) (0–1540) (0–60)
1 (7.1%) 1 (7.1%) 11 (78.6%)
Analysis of longitudinal changes in M. perstans microfilaraemia from baseline (Wilcoxon Signed Rank tests):
Doxycycline + ivermectin: p = 0.033 (* 4 month); p = 0.002 (** 12 month); p = 0.015 (* 21 month).
Ivermectin: p = 0.028 (* 4 month); p = 0.069 (ns, 12 month); p = 0.001 (*** 21 month).
Analysis of differences in M. perstans microfilaraemia between treatment groups at baseline, 4, 12 and 21 months post treatment (Mann Whitney U tests):
Doxycycline + ivermectin vs ivermectin: p = 0.418 (ns, baseline); p = 0.358 (ns, 4 month); p,0.001 (*** 12 month); p = 0.843 (ns, 21 month).
Analysis of frequency M. perstans amicrofilaraemia between treatment groups at 12 and 21 months post treatment (Fisher exact tests):
Doxycycline + ivermectin vs ivermectin: p = 0.424 (ns, 4 months); p,0.001 (***12 month); p = 1.000 (ns, 21 month).
doi:10.1371/journal.pntd.0000660.t009
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that M. perstans is host to Wolbachia endosymbionts and a 6-
week course of doxycycline leads to depletion of Wolbachia and
microfilaraemia [32]. Although we were unable to confirm the
presence of Wolbachia in M. perstans due to technical reasons,
the observations of the changes to microfilaraemia at the 12-
month follow up would be consistent with the presence and
dependency of Wolbachia in M. perstans.
If the elimination of onchocerciasis and lymphatic filariasis (W.
bancrofti) as a public health problem is to be achieved in Africa, a
solution to the problem of L. loa co-endemicity in Central Africa
has to be found. Attempts to use regimes of low dose ivermectin
have failed to provide sufficient reductions in mf suitable for MDP
and are probably inadequate to prevent the occurrence of post-
treatment neurological SAEs [33]. Further trials are currently
underway with albendazole, which can reduce L. loa microfila-
raemia following a twice-daily 21-day course [34]. Shorter 3-day
treatments with albendazole failed to lead to sufficient reductions
safe enough for ivermectin treatment [35,36] and so alternative
regimes are required.
One such regime, which we have demonstrated in this trial, is
the targeting of onchocerciasis with anti-wolbachial therapy.
Current regimes with doxycycline are restricted for widespread
MDA due to contraindications in children under 8 years old and
pregnancy and the logistics of 4–6 week courses of treatment.
Trials to evaluate the minimum effective course of treatment with
combinations of doxycycline and rifampicin in onchocerciasis is
currently underway as part of the A-WOL drug discovery and
development programme, which aims to optimise current anti-
wolbachial drugs and discover new drugs with a more rapid
efficacy and without the contra-indications of doxycycline [37], (A-
WOL.com). In addition, community directed intervention (CDI)
trials using a 6-week course of doxycycline have been completed
Figure 5. Changes in Mansonella perstans microfilaridermia from baseline at 4 months, 12 months and 21 months post treatment
with doxycycline + ivermectin, doxycycline only or ivermectin only. Arrows indicate commencement of intervention (black arrow;
doxycycline, red arrow; ivermectin).
doi:10.1371/journal.pntd.0000660.g005
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and challenge the notion that prolonged courses of treatment
cannot be effectively delivered through CDI [38]. It may be
possible to use RAPLOA, a rapid diagnostic tool, to map areas of
high risk of encephalopathy to define restricted areas where these
regimes could be deployed. Such regimes can already be
considered as a suitable treatment for individual cases of
onchocerciasis or LF in patients co-infected with L. loa and the
further development of anti-wolbachial regimes compatible with
MDA could offer an alternative tool for the control on
onchocerciasis and LF in Africa.
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